Table 2.
Log-rank test and univariate analysis of RNAMethyPro risk score in each cohort analyzed for internal or external validation
| Cancer type | Cohort | P valuea | HRa (95% CI) | P valueb | P value of risk scorec |
|---|---|---|---|---|---|
| Colorectal cancer | TCGA-COADREAD | 8.14E−03 | 2.15 (1.20–33.83) | 9.25E−03 | 3.06E−03 |
| Colorectal cancer | CIT | 1.53E−03 | 2.24 (1.34–3.74) | 4.68E−03 | 4.17E−03 |
| Gastric cancer | TCGA-STAD | 1.95E−05 | 11.98 (2.81–51.07) | 2.41E−04 | 3.22E−05 |
| Gastric cancer | ACRG-GC | 1.36E−02 | 1.78 (1.12–2.83) | 3.83E−02 | 3.23E−03 |
| Breast cancer | METABRIC Discovery | 2.10E−09 | 3.96 (2.43–6.44) | 2.04E−09 | 1.09E−09 |
| Breast cancer | METABRIC Validation | 9.46E−03 | 1.73 (1.14–2.63) | 2.17E−02 | 3.95E−03 |
| Ovarian cancer | MAYO-OV | 4.21E−03 | 1.91 (1.22–2.99) | 1.24E−02 | 1.81E−03 |
| Ovarian cancer | TCGA-OV | 3.17E−02 | 1.56 (1.04–2.35) | 8.22E−02 | 5.37E−01 |
| Pancreatic adenocarcinoma | TCGA-PAAD | 2.19E−03 | 4.48 (1.59–12.65) | 6.62E−03 | 2.80E−03 |
| Hepatocellular carcinoma | TCGA-LIHC | 4.36E−04 | 2.25 (1.42–3.57) | 1.19E−04 | 4.27E−06 |
| Lung adenocarcinoma | TCGA-LUAD | 4.97E−04 | 2.51 (1.47–4.28) | 3.97E−04 | 4.25E−05 |
| Bladder urothelial carcinoma | TCGA-BLCA | 2.83E−04 | 3.08 (1.63–5.84) | 1.32E−03 | 4.73E−03 |
| Head and neck squamous cell carcinoma | TCGA-HNSC | 2.18E−07 | 3.27 (2.04–5.24) | 1.42E−07 | 2.35E−05 |
| Acute myeloid leukemia | TARGET-AML | 1.32E−04 | 2.2 (1.45–3.32) | 1.29E−04 | 1.99E−06 |
| Lung squamous cell carcinoma | TCGA-LUSC | 2.35E−02 | 4.79 (1.07–21.42) | 5.00E−02 | 2.26E−02 |
| Esophageal adenocarcinoma | TCGA-ESCA(EAC) | 1.78E−02 | NAd | 5.51E−02 | 5.31E−03 |
| Esophageal squamous cell carcinoma | TCGA-ESCA(ESCC) | 1.25E−02 | 6 (1.23–29.31) | 5.48E−02 | 1.39E−02 |
CI confidence interval, HR hazard ratio, NA not applicable
aLog-rank test (high-risk vs low-risk groups)
bLog-rank test (three groups)
cUnivariate Cox regression
dHR cannot be accurately estimated owing to insufficient sample size